143 related articles for article (PubMed ID: 35835634)
21. HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.
Yadav BS; Dahiya D; Kannan P; Goyal S; Laroiya I; Irrinki S; Singh NR; Sharma R
Trials; 2024 Jan; 25(1):21. PubMed ID: 38167339
[TBL] [Abstract][Full Text] [Related]
22. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis.
Lacas B; Bourhis J; Overgaard J; Zhang Q; Grégoire V; Nankivell M; Zackrisson B; Szutkowski Z; Suwiński R; Poulsen M; O'Sullivan B; Corvò R; Laskar SG; Fallai C; Yamazaki H; Dobrowsky W; Cho KH; Beadle B; Langendijk JA; Viegas CMP; Hay J; Lotayef M; Parmar MKB; Aupérin A; van Herpen C; Maingon P; Trotti AM; Grau C; Pignon JP; Blanchard P;
Lancet Oncol; 2017 Sep; 18(9):1221-1237. PubMed ID: 28757375
[TBL] [Abstract][Full Text] [Related]
23. Variability of α/β ratios for prostate cancer with the fractionation schedule: caution against using the linear-quadratic model for hypofractionated radiotherapy.
Cui M; Gao XS; Li X; Ma M; Qi X; Shibamoto Y
Radiat Oncol; 2022 Mar; 17(1):54. PubMed ID: 35303922
[TBL] [Abstract][Full Text] [Related]
24. Practice changing data and emerging concepts from recent radiation therapy randomised clinical trials.
Espenel S; Chargari C; Blanchard P; Bockel S; Morel D; Rivera S; Levy A; Deutsch E
Eur J Cancer; 2022 Aug; 171():242-258. PubMed ID: 35779346
[TBL] [Abstract][Full Text] [Related]
25. Good clinical practice and the use of hypofractionation radiation schedules as weapons to reduce the risk of COVID-19 infections in radiation oncology unit: A mono-institutional experience.
Cozzi S; Ruggieri MP; Bardoscia L; Najafi M; Blandino G; Giaccherini L; Manicone M; Ramundo D; Rosca A; Solla DS; Botti A; Lambertini D; Ciammella P; Iotti C
J Cancer Res Ther; 2023; 19(3):644-649. PubMed ID: 37470588
[TBL] [Abstract][Full Text] [Related]
26. Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart.
Appelt AL; Vogelius IR; Bentzen SM
Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):147-52. PubMed ID: 22910644
[TBL] [Abstract][Full Text] [Related]
27. External beam radiation dose escalation for high grade glioma.
Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
[TBL] [Abstract][Full Text] [Related]
28. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
29. Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.
Wade R; South E; Anwer S; Sharif-Hurst S; Harden M; Fulbright H; Hodgson R; Dias S; Simmonds M; Rowe I; Thornton P; Eastwood A
Health Technol Assess; 2023 Dec; 27(29):1-172. PubMed ID: 38149643
[TBL] [Abstract][Full Text] [Related]
30. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
31. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
32. Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial.
Vreugdenhil M; Fong C; Sanghera P; Hartley A; Dunn J; Mehanna H
Oral Oncol; 2021 Feb; 113():105112. PubMed ID: 33321287
[TBL] [Abstract][Full Text] [Related]
33. The minimal FLASH sparing effect needed to compensate the increase of radiobiological damage due to hypofractionation for late-reacting tissues.
Böhlen TT; Germond JF; Bourhis J; Bailat C; Bochud F; Moeckli R
Med Phys; 2022 Dec; 49(12):7672-7682. PubMed ID: 35933554
[TBL] [Abstract][Full Text] [Related]
34. Hypofractionated radiotherapy in the real-world setting: An international ESTRO-GIRO survey.
Rodin D; Tawk B; Mohamad O; Grover S; Moraes FY; Yap ML; Zubizarreta E; Lievens Y
Radiother Oncol; 2021 Apr; 157():32-39. PubMed ID: 33453312
[TBL] [Abstract][Full Text] [Related]
35. Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments.
Chuong MD; Clark MA; Henke LE; Kishan AU; Portelance L; Parikh PJ; Bassetti MF; Nagar H; Rosenberg SA; Mehta MP; Refaat T; Rineer JM; Smith A; Seung S; Zaki BI; Fuss M; Mak RH
Clin Transl Radiat Oncol; 2023 Jan; 38():161-168. PubMed ID: 36466748
[TBL] [Abstract][Full Text] [Related]
36. Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiosurgery (SRS) to the resection cavity of brain metastases after surgical resection (SATURNUS): study protocol for a randomized phase III trial.
Waltenberger M; Bernhardt D; Diehl C; Gempt J; Meyer B; Straube C; Wiestler B; Wilkens JJ; Zimmer C; Combs SE
BMC Cancer; 2023 Jul; 23(1):709. PubMed ID: 37516835
[TBL] [Abstract][Full Text] [Related]
37. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
[TBL] [Abstract][Full Text] [Related]
38. Systematic review of hypofractionated radiation therapy for prostate cancer.
Zaorsky NG; Ohri N; Showalter TN; Dicker AP; Den RB
Cancer Treat Rev; 2013 Nov; 39(7):728-36. PubMed ID: 23453861
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic ablative body radiotherapy for lung cancer.
Franks KN; Jain P; Snee MP
Clin Oncol (R Coll Radiol); 2015 May; 27(5):280-9. PubMed ID: 25746732
[TBL] [Abstract][Full Text] [Related]
40. Cellular bases of hypofractionated radiotherapy protocols for lung cancer.
Ocolotobiche EE; Banegas YC; Ferraris G; Martínez M; Güerci AM
An Acad Bras Cienc; 2022; 94(4):e20210056. PubMed ID: 35894359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
